Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE) announced that CEO Markus Warmuth, M.D. will participate in fireside chats at four investor conferences in November–December 2025.

Scheduled participations: Guggenheim Healthcare Innovation (Boston) on Nov 10, 2025 at 11:30 a.m. ET; TD Cowen Immunology & Inflammation Summit (virtual) on Nov 13, 2025 at 12:00 p.m. ET; Jefferies Global Healthcare (London) on Nov 18, 2025 at 11:30 a.m. GMT; and Piper Sandler Healthcare (New York) on Dec 2, 2025 at 1:30 p.m. ET.

Webcasts will be available via the company’s Events & Presentations page at ir.monterosatx.com and archived for 30 days after each presentation.

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences:

• Guggenheim 2^nd Annual Healthcare Innovation Conference (Boston, MA) – November 10, 2025, at 11:30 a.m. ET
• TD Cowen Immunology & Inflammation Summit (virtual) – November 13, 2025, at 12:00 p.m. ET
• Jefferies Global Healthcare Conference in London – November 18, 2025, at 11:30 a.m. GMT
• Piper Sandler 37^th Annual Healthcare Conference (New York, NY) – December 2, 2025, at 1:30 p.m. ET

Webcasts of the fireside chats will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

When will Monte Rosa Therapeutics (GLUE) present at the Guggenheim Healthcare Innovation Conference?

Monte Rosa will present on November 10, 2025 at 11:30 a.m. ET with CEO Markus Warmuth participating in a fireside chat.

How can investors watch Monte Rosa Therapeutics (GLUE) at the TD Cowen Immunology & Inflammation Summit on November 13, 2025?

The TD Cowen session is virtual and will be webcast; access it via the Events & Presentations page at ir.monterosatx.com at 12:00 p.m. ET.

What time is Monte Rosa Therapeutics (GLUE) scheduled to speak at Jefferies Global Healthcare Conference in London?

The Jefferies presentation is scheduled for November 18, 2025 at 11:30 a.m. GMT with CEO Markus Warmuth in a fireside chat.

Will Monte Rosa Therapeutics (GLUE) provide webcasts of the Piper Sandler conference presentation on December 2, 2025?

Yes. The Piper Sandler fireside chat on Dec 2, 2025 at 1:30 p.m. ET will be webcast and archived on the company’s IR site for 30 days.

Where can archived webcasts of Monte Rosa Therapeutics (GLUE) investor presentations be found and for how long?

Archived webcasts are available on the Events & Presentations page at ir.monterosatx.com and will remain for 30 days after each presentation.